Sugimoto, Toshitsugu
Matsumoto, Toshio
Hosoi, Takayuki
Shiraki, Masataka
Kobayashi, Makiko
Okubo, Naoki
Takami, Hideo
Nakamura, Toshitaka
Funding for this research was provided by:
Daiichi Sankyo Company
Article History
Received: 24 March 2020
Accepted: 6 June 2020
First Online: 15 July 2020
Compliance with ethical standards
:
: Dr. T. Sugimoto has received research grants from Astellas Pharma, Eisai, Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., and Eli Lilly Japan, as well as consulting and/or lecture fees from Asahi Kasei Pharma Co., Ltd., and Daiichi Sankyo Co., Ltd. Dr. T. Matsumoto has received consulting fees from Daiichi Sankyo Co., Ltd., Astellas Amgen Biopharma Co. Ltd., Chugai Pharmaceutical Co., Ltd., and Teijin Pharma. Dr. T. Hosoi has received consulting fees from Daiichi Sankyo Co., Ltd. Dr. M. Shiraki has received consulting fees from Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., Teijin Pharma, Asahi Kasei Pharma Co., Ltd., and MSD. Dr. M. Kobayashi, Dr. N. Okubo, and Dr. H. Takami are employees of Daiichi Sankyo Co., Ltd., Tokyo, Japan. Dr. T. Nakamura acted as a consultant for Teijin Pharma, Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., Asahi Kasei Pharma Co., Ltd., and Amgen Inc.